Testing effectiveness (Phase 2)Ended earlyNCT01602315
What this trial is testing
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Novartis Pharmaceuticals 179